Xarelto Cases Settle for $775 Million
Johnson & Johnson and Bayer pharmaceuticals have agreed to split a $775 million settlement over Xarelto, a blood thinner which earned J&J nearly $2.5 billion in 2018 alone.
The Maher Law Firm—and the attorneys involved in the 25,000 cases across the country—claim that the Big Pharma companies failed to warn patients that Xarelto, which thins the blood to prevent clots that lead to strokes, can cause patients to have continuous bleeding episodes, potentially leading to life-altering injuries or even death. Until recently, there was no approved antidote to stop the bleeding caused by Xarelto.
Complicating the case further, questions had been raised about whether the clinical trials conducted prior to Xarelto’s approval were valid. After the trials, the blood-testing monitors used were found to be faulty.
Though neither company involved admitted liability, we are pleased with this settlement and are happy that our clients receive some financial compensation for their hardships.